| Aug 28 |
Adaptimmune to Participate in Two Bank Conferences this September
|
| Aug 15 |
Adaptimmune Therapeutics (NASDAQ:ADAP) investors are sitting on a loss of 74% if they invested three years ago
|
| Aug 12 |
Adaptimmune Therapeutics plc (ADAP) Q2 2024 Earnings Call Transcript
|
| Aug 12 |
ADAP: 2Q24 Earnings Review: Tecelra FDA Approval + Capital Reload
|
| Aug 12 |
Earnings summary: Adaptimmune Therapeutics beats Q2 estimates
|
| Aug 12 |
Adaptimmune GAAP EPS of $0.04 beats by $0.04, revenue of $128.2M beats by $83.44M
|
| Aug 12 |
Adaptimmune Reports Q2 2024 Financial and Business Updates
|
| Aug 9 |
Adaptimmune Q2 2024 Earnings Preview
|
| Aug 9 |
Adaptimmune leads in soft tissue sarcoma therapy with first TCR approval
|
| Aug 5 |
Adaptimmune to Report Q2 2024 Financial and Business Updates on Monday, August 12, 2024
|
